Palestine
· Delayed Price · Currency is JOD · Price in USDBPC Statistics
Total Valuation
Birzeit Pharmaceuticals Company has a market cap or net worth of JOD 102.97 million. The enterprise value is 94.29 million.
| Market Cap | 102.97M |
| Enterprise Value | 94.29M |
Important Dates
The last earnings date was Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Birzeit Pharmaceuticals Company has 38.76 million shares outstanding. The number of shares has increased by 1.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 38.76M |
| Shares Change (YoY) | +1.00% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 23.26% |
| Owned by Institutions (%) | n/a |
| Float | 23.90M |
Valuation Ratios
The trailing PE ratio is 38.89.
| PE Ratio | 38.89 |
| Forward PE | n/a |
| PS Ratio | 3.66 |
| PB Ratio | 1.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 36.86 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.63, with an EV/FCF ratio of 33.75.
| EV / Earnings | 37.24 |
| EV / Sales | 3.50 |
| EV / EBITDA | 17.63 |
| EV / EBIT | 21.72 |
| EV / FCF | 33.75 |
Financial Position
The company has a current ratio of 7.02
| Current Ratio | 7.02 |
| Quick Ratio | 5.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 605.62 |
Financial Efficiency
Return on equity (ROE) is 3.47% and return on invested capital (ROIC) is 3.69%.
| Return on Equity (ROE) | 3.47% |
| Return on Assets (ROA) | 3.11% |
| Return on Capital (ROIC) | 3.69% |
| Revenue Per Employee | 89,598 |
| Profits Per Employee | 8,439 |
| Employee Count | 300 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -6.50% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 47.42 |
| Average Volume (20 Days) | 5,007 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Birzeit Pharmaceuticals Company had revenue of JOD 26.88 million and earned 2.53 million in profits. Earnings per share was 0.07.
| Revenue | 26.88M |
| Gross Profit | 9.10M |
| Operating Income | 4.33M |
| Pretax Income | 3.08M |
| Net Income | 2.53M |
| EBITDA | 5.33M |
| EBIT | 4.33M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
| Cash & Cash Equivalents | 9.15M |
| Total Debt | n/a |
| Net Cash | 9.15M |
| Net Cash Per Share | 0.24 |
| Equity (Book Value) | 70.56M |
| Book Value Per Share | 1.83 |
| Working Capital | 40.31M |
Cash Flow
In the last 12 months, operating cash flow was 3.68 million and capital expenditures -884,525, giving a free cash flow of 2.79 million.
| Operating Cash Flow | 3.68M |
| Capital Expenditures | -884,525 |
| Free Cash Flow | 2.79M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 33.86%, with operating and profit margins of 16.09% and 9.42%.
| Gross Margin | 33.86% |
| Operating Margin | 16.09% |
| Pretax Margin | 11.47% |
| Profit Margin | 9.42% |
| EBITDA Margin | 19.83% |
| EBIT Margin | 16.09% |
| FCF Margin | 10.39% |
Dividends & Yields
Birzeit Pharmaceuticals Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -50.08% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 54.18% |
| Buyback Yield | -1.00% |
| Shareholder Yield | -1.00% |
| Earnings Yield | 2.56% |
| FCF Yield | 2.71% |
Stock Splits
The last stock split was on April 21, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Apr 21, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |